EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

NEAT1 lncRNA overexpression results in short‐term progression and poor treatment outcome in childhood B‐ ALL

Marieta Xagorari, Antonios Marmarinos, Dimitrios Doganis, Maria Nikita, Evgenia Magkou, Angeliki-Eleni Sfetsiori, Margarita Baka, Lydia Kossiva, Sofia Pasparaki, Alexandra Soldatou, Maria Tsolia, Andreas Scorilas iD und 2 weitere

British Journal of Haematology · 2025

DOI: 10.1111/bjh.70127 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Haematology, 2025. Verfasst von Marieta Xagorari und 13 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Clinical Biochemistry-Molecular Diagnostics, Second Department of Pediatrics, School of Medicine, National and Kapodistrian University …. Hauptthemen laut MEDLINE: RNA, Long Noncoding, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Gene Expression Regulation, Leukemic. Die Arbeit nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Childhood acute lymphoblastic leukaemia (chALL) remains the most prevalent malignancy in children and adolescents. Improving risk stratification and providing personalized prognosis and treatment remain major clinical challenges. Herein, we analysed the clinical utility of NEAT1 lncRNA for the prognosis and prediction of treatment outcome of childhood B‐cell precursor ALL (chB‐ALL). NEAT1_1 isoform was quantified in bone marrow samples of chB‐ALL patients at diagnosis ( n = 160) and at the end of induction ( n = 108) of ALL‐BFM protocol, and in age‐matched healthy children ( n = 68). Relapse and death served as clinical end‐points for survival analysis. Bootstrap analysis was performed for internal validation and decision curve analysis assessed the clinical net benefit for chB‐ALL prognosis. Our analysis showed that chB‐ALL patients with NEAT1 overexpression at diagnosis are at significantly higher risk for progression (HR = 2.957, 95% CI: 1.122–7.790, p = 0.011) and worse survival (HR = 5.832, 95% CI: 1.259–27.01, p = 0.012), independently of clinicopathological and treatment data. Moreover, NEAT1‐fitted multivariate models resulted in improved risk stratification compared to the conventional disease markers of white blood cells, bone marrow response and minimal residual disease, while decision curve analysis highlighted the superior clinical net benefit for chB‐ALL prognosis. In conclusion, NEAT1 overexpression constitutes a powerful, independent predictor of poor treatment outcomes and disease progression of chB‐ALL, providing refined stratification of patient's risk.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RNA, Long NoncodingPrecursor B-Cell Lymphoblastic Leukemia-LymphomaGene Expression Regulation, LeukemicHumansChildMaleFemaleChild, PreschoolAdolescentDisease ProgressionPrognosisTreatment OutcomeInfantBiomarkers, Tumor

Stichwörter der Autor:innen

ALL IC‐BFMBFMNEAT1_1childhood leukaemialeukaemialong non‐coding RNAnon‐coding RNAnuclear enriched abundant transcript 1paediatric leukaemia

Substanzen

RNA, Long NoncodingNEAT1 long non-coding RNA, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Laboratory of Clinical Biochemistry-Molecular Diagnostics, Second Department of Pediatrics, School of Medicine, National and Kapodistrian University of Athens, 'P. & A. Kyriakou' Children's Hospital, Athens, Greece.
  • Department of Pediatric Oncology, 'P. & A. Kyriakou' Children's Hospital, Athens, Greece.
  • Second Department of Pediatrics, School of Medicine, National and Kapodistrian University of Athens, 'P. & A. Kyriakou' Children's Hospital, Athens, Greece.
  • Department of Biochemistry and Molecular Biology, Faculty of Biology, National and Kapodistrian University of Athens, Athens, Greece.

ORCID-Profile: Andreas Scorilas, Margaritis Avgeris

Zitieren

APA

Xagorari, M., Marmarinos, A., Doganis, D., Nikita, M., Magkou, E., Sfetsiori, A. E., Baka, M., Kossiva, L., Pasparaki, S., Soldatou, A., Tsolia, M., Scorilas, A., Gourgiotis, D., & Avgeris, M. (2025). NEAT1 lncRNA overexpression results in short‐term progression and poor treatment outcome in childhood B‐ ALL. British Journal of Haematology. https://doi.org/10.1111/bjh.70127

Vancouver

Xagorari M, Marmarinos A, Doganis D, Nikita M, Magkou E, Sfetsiori AE, et al. NEAT1 lncRNA overexpression results in short‐term progression and poor treatment outcome in childhood B‐ ALL. British Journal of Haematology. 2025. doi:10.1111/bjh.70127

BibTeX
@article{Xagorari2025,
  author = {Xagorari, Marieta and Marmarinos, Antonios and Doganis, Dimitrios and Nikita, Maria and Magkou, Evgenia and Sfetsiori, Angeliki-Eleni and Baka, Margarita and Kossiva, Lydia and Pasparaki, Sofia and Soldatou, Alexandra and Tsolia, Maria and Scorilas, Andreas and Gourgiotis, Dimitrios and Avgeris, Margaritis},
  title = {NEAT1 lncRNA overexpression results in short‐term progression and poor treatment outcome in childhood B‐ ALL},
  journal = {British Journal of Haematology},
  year = {2025},
  doi = {10.1111/bjh.70127}
}
Kostenlos starten →